Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00262-012-1330-5, but it redirected us to https://link.springer.com/article/10.1007/s00262-012-1330-5. The analysis below is for the second page.

Title[redir]:
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment | Cancer Immunology, Immunotherapy
Description:
Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4+CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, google, scholar, cancer, pubmed, cas, prostate, blockade, patients, cell, cells, ctla, immunotherapy, clin, survival, regulatory, van, allison, oncol, metastatic, clinical, immunol, ipilimumab, melanoma, res, usa, lowy, antigen, small, treatment, eertwegh, phase, trial, med, weber, effector, privacy, cookies, content, analysis, gvaxipilimumab, santegoets, hege, blomberg, scheper, gruijl, immune, checkpoint, biomarkers, castrationresistant,

Topics {✒️}

poxviral-based psa-targeted immunotherapy month download article/chapter nj/bristol-myers squibb company prostate gvax/ipilimumab treatment castration-resistant prostate cancer prostate gvax/ipilimumab therapy hormone-refractory prostate cancer high pre-treatment frequencies patient selection prior anti-cytotoxic t-lymphocyte antigen-4 allogeneic cellular immunotherapy article cancer immunology hormone-naive prostate cancer bristol-myers squibb employee low pre-treatment frequencies jean-marie cuillerot van den eertwegh cancer immunotherapy cd8-positive related subjects anti-ctla-4 antibodies full article pdf immune checkpoint blockade progressive prostate cancer prostate cancer foundation immune checkpoint proteins human anti-ctla-4 autoimmune adverse events advanced prostate cancer asco meeting abstract privacy choices/manage cookies bristol-myers squibb anti-ctla4 antibody t-cell inhibition helper cell responses single-cell analysis ctla-4 blockade synergizes preoperative ctla-4 blockade tumour immunotherapy dose-dependent fashion cancer–preclinical background cancer vaccine failure dutch cancer society kantoff pw presurgical clinical trial cells cd4-positive van moorselaar rj experimental mammary carcinoma immunotherapy article de gruijl td cell intrinsic mechanisms

Schema {🗺️}

WebPage:
      mainEntity:
         headline:T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
         description:Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4+CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.
         datePublished:2012-08-10T00:00:00Z
         dateModified:2012-08-10T00:00:00Z
         pageStart:245
         pageEnd:256
         sameAs:https://doi.org/10.1007/s00262-012-1330-5
         keywords:
            Ipilimumab
            Prostate GVAX
            Biomarker
            Patient selection
            Survival prediction
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:62
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Saskia J. A. M. Santegoets
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Anita G. M. Stam
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sinéad M. Lougheed
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Helen Gall
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Petra E. T. Scholten
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Martine Reijm
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karin Jooss
               affiliation:
                     name:Cell Genesys Inc.
                     address:
                        name:Cell Genesys Inc., South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Natalie Sacks
               affiliation:
                     name:Cell Genesys Inc.
                     address:
                        name:Cell Genesys Inc., South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kristen Hege
               affiliation:
                     name:Cell Genesys Inc.
                     address:
                        name:Cell Genesys Inc., South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Israel Lowy
               affiliation:
                     name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
                     address:
                        name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jean-Marie Cuillerot
               affiliation:
                     name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
                     address:
                        name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:B. Mary E. von Blomberg
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rik J. Scheper
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alfons J. M. van den Eertwegh
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Winald R. Gerritsen
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tanja D. de Gruijl
               affiliation:
                     name:VU University Medical Center
                     address:
                        name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
      description:Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4+CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.
      datePublished:2012-08-10T00:00:00Z
      dateModified:2012-08-10T00:00:00Z
      pageStart:245
      pageEnd:256
      sameAs:https://doi.org/10.1007/s00262-012-1330-5
      keywords:
         Ipilimumab
         Prostate GVAX
         Biomarker
         Patient selection
         Survival prediction
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1330-5/MediaObjects/262_2012_1330_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:62
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Saskia J. A. M. Santegoets
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Anita G. M. Stam
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sinéad M. Lougheed
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Helen Gall
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Petra E. T. Scholten
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Martine Reijm
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karin Jooss
            affiliation:
                  name:Cell Genesys Inc.
                  address:
                     name:Cell Genesys Inc., South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Natalie Sacks
            affiliation:
                  name:Cell Genesys Inc.
                  address:
                     name:Cell Genesys Inc., South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kristen Hege
            affiliation:
                  name:Cell Genesys Inc.
                  address:
                     name:Cell Genesys Inc., South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Israel Lowy
            affiliation:
                  name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
                  address:
                     name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jean-Marie Cuillerot
            affiliation:
                  name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
                  address:
                     name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:B. Mary E. von Blomberg
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rik J. Scheper
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alfons J. M. van den Eertwegh
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Winald R. Gerritsen
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tanja D. de Gruijl
            affiliation:
                  name:VU University Medical Center
                  address:
                     name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:62
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:Cell Genesys Inc.
      address:
         name:Cell Genesys Inc., South San Francisco, USA
         type:PostalAddress
      name:Cell Genesys Inc.
      address:
         name:Cell Genesys Inc., South San Francisco, USA
         type:PostalAddress
      name:Cell Genesys Inc.
      address:
         name:Cell Genesys Inc., South San Francisco, USA
         type:PostalAddress
      name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
      address:
         name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
         type:PostalAddress
      name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
      address:
         name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
      name:VU University Medical Center
      address:
         name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Saskia J. A. M. Santegoets
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Anita G. M. Stam
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Sinéad M. Lougheed
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Helen Gall
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Petra E. T. Scholten
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Martine Reijm
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Karin Jooss
      affiliation:
            name:Cell Genesys Inc.
            address:
               name:Cell Genesys Inc., South San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Natalie Sacks
      affiliation:
            name:Cell Genesys Inc.
            address:
               name:Cell Genesys Inc., South San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Kristen Hege
      affiliation:
            name:Cell Genesys Inc.
            address:
               name:Cell Genesys Inc., South San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Israel Lowy
      affiliation:
            name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
            address:
               name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
               type:PostalAddress
            type:Organization
      name:Jean-Marie Cuillerot
      affiliation:
            name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company
            address:
               name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
               type:PostalAddress
            type:Organization
      name:B. Mary E. von Blomberg
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Rik J. Scheper
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Alfons J. M. van den Eertwegh
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Winald R. Gerritsen
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Tanja D. de Gruijl
      affiliation:
            name:VU University Medical Center
            address:
               name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Cell Genesys Inc., South San Francisco, USA
      name:Cell Genesys Inc., South San Francisco, USA
      name:Cell Genesys Inc., South San Francisco, USA
      name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
      name:Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, USA
      name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
      name:Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(254)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.32s.